Showing results (491-500 of 631) with videos related to

Sort By:
Pageof 64
Circulation|January 21, 1997
Recombinant staphylokinase variants with altered immunoreactivity. III: Species variability of antibody binding patternsD Collen, F De Cock, E Demarsin, et al.
Thrombosis Research|February 1, 1992
K1K2Pu, a recombinant t-PA/u-PA chimera with increased thrombolytic potency, consisting of amino acids 1 to 3 and 87 to 274 of human tissue-type plasminogen activator (t-PA) and amino acids 138 to 411 of human single chain urokinase-type plasminogen activator (scu-PA). Purification in centigram quantities and conditioning for use in manD Collen, L Nelles, F De Cock, et al.
Neuroscience|August 17, 2002
Rapid, specific and active site-catalyzed effect of tissue-plasminogen activator on hippocampus-dependent learning in miceR Pawlak, N Nagai, T Urano, et al.
Metabolism: Clinical and Experimental|March 1, 1986
Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjectsP Vague, I Juhan-Vague, M F Aillaud, et al.
The Journal of Biological Chemistry|March 31, 1995
Retinoic acid induction of human tissue-type plasminogen activator gene expression via a direct repeat element (DR5) located at -7 kilobasesF Bulens, I Ibañez-Tallon, P Van Acker, et al.
Gene Therapy|January 20, 2007
Species differences in transgene DNA uptake in hepatocytes after adenoviral transfer correlate with the size of endothelial fenestraeJ Snoeys, J Lievens, E Wisse, et al.
The Journal of Biological Chemistry|June 25, 1991
On the mechanism of fibrin-specific plasminogen activation by staphylokinaseH R Lijnen, B Van Hoef, F De Cock, et al.
Circulation|June 1, 1987
A randomized, blinded, placebo-controlled trial of recombinant human tissue-type plasminogen activator in patients with unstable angina pectorisH K Gold, J A Johns, R C Leinbach, et al.
Nature Medicine|September 30, 1999
Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failureS Heymans, A Luttun, D Nuyens, et al.
Early Human Development|February 26, 2010
Antenatal fetal VEGF therapy to promote pulmonary maturation in a preterm rabbit modelA Debeer, L Sbragia, K Vrancken, et al.
Pageof 64